US EditionPublished • loading... • Updated
NRG doses first participants in Phase I trial for ALS and Parkinson’s
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
NRG doses first participants in Phase I trial for ALS and Parkinson’s
NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a disease-modifying treatment for MND and Parkinson’s.The post NRG doses first participants in Phase I trial for ALS and Parkinson’s appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
